About Cardea Bio
Cardea Bio is a company based in San Diego (United States) founded in 2019 by Brett Goldsmith was acquired by Paragraf in May 2023. Cardea Bio has raised $21.8 million across 4 funding rounds from investors including ARE, Agilent and Paragraf. Cardea Bio has completed 1 acquisition, including Nanosens Innovations. Cardea Bio operates in a competitive market with competitors including Hememics Biotechnologies, Nix, Aligned Bio, Monod and Olaris, among others.
- Headquarter San Diego, United States
- Founders Brett Goldsmith
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Cardea Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Cardea Bio
Cardea Bio has successfully raised a total of $21.8M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $1.1 million completed in May 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cardea Bio
Cardea Bio has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include ARE, Agilent and Paragraf.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Tech & Life Science focused early & growth stage VC firm investing in the US & China
|
Locked | Locked | Locked | |
|
Venture capital fund focused on Agtech and multiple sectors
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Cardea Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cardea Bio
Cardea Bio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Nanosens Innovations.
Investment portfolio details for Cardea Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Nanosize biosensors are developed for biological sample analysis.
|
Locked | Locked | 2006 | Locked |
Complete acquisition details for Cardea Bio
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Cardea Bio
Detailed financials for Cardea Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cardea Bio Comparisons
Peer comparison for Cardea Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cardea Bio
Cardea Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Hememics Biotechnologies, Nix, Aligned Bio, Monod and Olaris, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biopreservation platform for mammalian cells and biologics is developed.
|
|
| Locked | Locked | Locked |
Sweat-based biosensors are provided for body hydration monitoring.
|
|
| Locked | Locked | Locked |
Nanowire-based sensors and alignment technologies are provided for molecular detection.
|
|
| Locked | Locked | Locked |
Developer of biosensors to detect viral proteins, toxins, antibodies, and other molecules
|
|
| Locked | Locked | Locked |
In-vitro diagnostics are developed for oncology, transplants, and neurodegeneration.
|
Detailed competitors of Cardea Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cardea Bio
Complete news archive for Cardea Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cardea Bio
Cardea Bio was founded in 2019.
Cardea Bio is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Cardea Bio is a funded company, having raised a total of $21.8M across 4 funding rounds to date.
Cardea Bio was founded in 2019 in San Diego, United States. Digital graphene biosensors are created through integration of machine learning. Biology-gated transistors, based on patented Field Effect Biosensing technology, form the core products. Chipsets such as CRISPR-Chip are manufactured using this approach. Molecular biology, graphene, nano-physics, electronics, software, and AI are combined in the platform to enable signal detection systems.
Cardea Bio has made 1 acquisition, including Nanosens Innovations.
Cardea Bio has 10 investors. Key investors include ARE, Agilent, Paragraf, Gates Foundation, and 3E Bioventures Capital.